ImmunityBio, Inc. (IBRX) is a clinical-stage biopharmaceutical company focused on developing next-generation therapies and vaccines that harness the immune system to combat cancers and infectious diseases. Its approved product, ANKTIVA, is commercialized for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC). The company's Cancer BioShield platform encompasses cytokine fusion proteins, DNA and recombinant protein vaccines, and cell therapies including NK cell-based treatments.
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-23 | 2025-12-31 | 0001326110-26-000030 | EDGAR | 153K words |
| 2025-03-03 | 2024-12-31 | 0001326110-25-000033 | EDGAR | 159K words |
| 2024-03-19 | 2023-12-31 | 0001326110-24-000037 | EDGAR | 144K words |
| 2023-03-01 | 2022-12-31 | 0001326110-23-000018 | EDGAR | 139K words |
| 2022-03-01 | 2021-12-31 | 0001326110-22-000011 | EDGAR | — |
| 2021-03-04 | 2020-12-31 | 0001564590-21-010945 | EDGAR | — |
| 2020-03-25 | 2019-12-31 | 0001564590-20-012816 | EDGAR | — |
| 2019-03-13 | 2018-12-31 | 0001564590-19-007562 | EDGAR | — |
| 2018-03-12 | 2017-12-31 | 0001564590-18-005290 | EDGAR | — |
| 2017-03-15 | 2016-12-31 | 0001564590-17-004430 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-04 | 2026-06-30 | 0001326110-26-000079 | EDGAR | 93K words |
| 2025-11-05 | 2025-09-30 | 0001326110-25-000139 | EDGAR | 110K words |
| 2025-08-05 | 2025-06-30 | 0001326110-25-000114 | EDGAR | 109K words |
| 2025-05-12 | 2025-03-31 | 0001326110-25-000071 | EDGAR | 103K words |
| 2024-11-12 | 2024-09-30 | 0001326110-24-000111 | EDGAR | 96K words |
| 2024-08-12 | 2024-06-30 | 0001326110-24-000103 | EDGAR | 94K words |
| 2024-05-09 | 2024-03-31 | 0001326110-24-000064 | EDGAR | 88K words |
| 2023-11-09 | 2023-09-30 | 0001326110-23-000147 | EDGAR | 98K words |
| 2023-08-08 | 2023-06-30 | 0001326110-23-000098 | EDGAR | 93K words |
| 2023-05-11 | 2023-03-31 | 0001326110-23-000064 | EDGAR | 87K words |
| 2022-11-09 | 2022-09-30 | 0001326110-22-000074 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001326110-22-000058 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-04 | 0001326110-26-000077 | EDGAR | 4K words |
| 2026-07-30 | 0001326110-26-000071 | EDGAR | 3K words |
| 2026-04-06 | 0001193125-26-142932 | EDGAR | 1K words |
| 2026-03-31 | 0001193125-26-133363 | EDGAR | 1K words |
| 2026-02-23 | 0001326110-26-000025 | EDGAR | 5K words |
| 2026-02-18 | 0001326110-26-000018 | EDGAR | 2K words |
| 2026-01-26 | 0001326110-26-000014 | EDGAR | 1K words |
| 2026-01-15 | 0001326110-26-000008 | EDGAR | 1K words |
| 2026-01-14 | 0001326110-26-000004 | EDGAR | 1K words |
| 2025-12-29 | 0001193125-25-331244 | EDGAR | 1K words |
175 total filings indexed. 143 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001326110 |
| Ticker | IBRX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.immunitybio.com |
| Listed | 2021-03-10 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/IBRX (~200 tokens, structured JSON with cryptographic provenance)